(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition to the forefront, subsequent studies have examined combinations of immune checkpoint inhibitors in the first-line setting. In the Kidney and Bladder Poster Discussion session at the 2021 American Society of Clinical Oncology Annual Meeting, Dr. Xinan Sheng presented results from the phase III CONCEPT randomized controlled trial of vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma.